| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $2,687,839 ) |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA247375 | CDC7 kinase in normal and cancer cells: potential implications for cancer treatment | 000 | 4 | NIH | 11/15/2022 | $419,566 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K00CA234842 | Investigating molecular mechanism of immune response during cancer progression | 001 | 6 | NIH | 11/21/2022 | $93,150 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32CA254118 | Identifying Combination Therapies in Ovarian Tumors using High Throughput Dynamic BH3 Profiling | 000 | 3 | NIH | 11/28/2022 | $71,734 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 2 | NIH | 10/31/2022 | $1,176,696 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DK123228 | Cellular and Biochemical Pathways of Adipose Metabolism and Thermogenesis | 000 | 4 | NIH | 11/30/2022 | $479,030 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA236226 | Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment | 000 | 5 | NIH | 11/16/2022 | $429,879 |
| | 2023 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K01DK132455 | The Role of Mitochondrial TNAP in Adaptive Thermogenesis | 000 | 1 | NIH | 11/30/2022 | $129,001 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA267527 | Defining the impact of mutational drivers on the immune microenvironment of CLL | 000 | 1 | NIH | 12/1/2022 | $0 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K99DE030084 | Targeting mechanical regulation of monocyte fate in head and neck cancer. | 000 | 2 | NIH | 11/30/2022 | -$111,217 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | U24HG004059 | Bioconductor: An Open-Source, Open-Development Computing Resource for Genomics | 000 | 18 | NIH | 11/21/2022 | $0 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K00CA234842 | Investigating molecular mechanism of immune response during cancer progression | 000 | 5 | NIH | 10/14/2022 | $0 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | UH3AG060626 | Improving Advance Care Planning in Oncology: A Pragmatic, Cluster-Randomized Trial Integrating Patient Videos and Clinician Communication Training | 000 | 5 | NIH | 10/24/2022 | $0 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DK122833 | Genetic dissection of visceral pain pathways | 000 | 4 | NIH | 11/17/2022 | $0 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA233800 | Novel Screening Platform for Discovery of DUB Targeting Probes | 000 | 4 | NIH | 11/8/2022 | $0 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01AG071966 | Defining the landscape and mechanisms of protein redox regulation during aging | 000 | 1 | NIH | 11/22/2022 | $0 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | U01CA210171 | Altered metabolism and machine learning for pancreatic cancer early detection | 000 | 6 | NIH | 11/7/2022 | $0 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | UH3CA240688 | Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors | 000 | 3 | NIH | 11/15/2022 | $1 |
| | 2023 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA272982 | Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers | 000 | 1 | NIH | 12/2/2022 | $0 |
| | 2023 | 2021 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R56AG074527 | Mitochondrial Protein Translation Signaling and Survival Mechanisms | 000 | 5 | NIH | 11/1/2022 | $0 |
| | 2023 | 2021 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA216273 | (PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia | 000 | 5 | NIH | 10/11/2022 | $0 |
| | 2023 | 2021 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01NR016720 | PediQUEST: Improving Children's Quality of Life through e-PROMS and Palliative Care | 001 | 5 | NIH | 11/3/2022 | $0 |
| | 2023 | 2021 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01NR016720 | PediQUEST: Improving Children's Quality of Life through e-PROMS and Palliative Care | 000 | 5 | NIH | 11/3/2022 | $0 |
| | 2023 | 2020 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | UH2CA240688 | Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors | 000 | 2 | NIH | 11/15/2022 | -$1 |
| | 2023 | 2020 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA205954 | (PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS) | 000 | 5 | NIH | 12/2/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $155,394,031 ) (Continued on the next page) |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA270085 | Tracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining Transformation | 000 | 1 | NIH | 9/1/2022 | $189,000 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA245036 | Expectations for Pediatric Cancer Treatment (EXPECT): A Family-Centered Intervention to Prepare Parents for Pediatric Leukemia Therapy | 000 | 4 | NIH | 8/26/2022 | $152,029 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA260442 | Regulation and targeting of tumor cell states and plasticity in pancreatic cancer | 000 | 1 | NIH | 8/29/2022 | $260,247 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32DK132864 | Elucidating novel molecular mechanisms of irisin-mediated effects via integrin | 002 | 1 | NIH | 7/14/2022 | $1 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32DK132864 | Elucidating novel molecular mechanisms of irisin-mediated effects via integrin | 001 | 1 | NIH | 4/27/2022 | $0 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | F32DK132864 | Elucidating novel molecular mechanisms of irisin-mediated effects via integrin | 000 | 1 | NIH | 4/27/2022 | $67,581 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA263552 | Deciphering non-canonical translation in high risk medulloblastoma | 000 | 1 | NIH | 8/23/2022 | $226,800 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DE027736 | Immunotherapeutic responses to neoantigens in head and neck cancer | 000 | 5 | NIH | 3/2/2022 | $520,230 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DE027736 | Immunotherapeutic responses to neoantigens in head and neck cancer | 001 | 5 | NIH | 4/21/2022 | $52,027 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA271605 | Cell lineage as an indicator of immune response in neuroblastoma | 000 | 1 | NIH | 6/16/2022 | $405,378 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA265826 | Dana Farber/Harvard Cancer Center SPORE in Lung Cancer | 002 | 1 | NIH | 9/21/2022 | $47,499 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA265826 | Dana Farber/Harvard Cancer Center SPORE in Lung Cancer | 001 | 1 | NIH | 8/4/2022 | $0 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA265826 | Dana Farber/Harvard Cancer Center SPORE in Lung Cancer | 000 | 1 | NIH | 7/29/2022 | $2,336,838 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K99HL163396 | Mechanistic Understanding of Hypoxia-Induced Peroxisome loss: Implications for Heart Failure | 000 | 1 | NIH | 5/26/2022 | $149,850 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA259621 | Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer | 000 | 1 | NIH | 6/15/2022 | $211,308 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA259538 | A Novel Intervention for Avoidance-Related Opioid Misuse in Patients with Cancer | 000 | 1 | NIH | 6/28/2022 | $152,737 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 000 | 1 | NIH | 2/24/2022 | $525,969 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00GM135519 | De novo design of small-molecule-binding proteins | 000 | 3 | NIH | 8/12/2022 | $249,000 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA273123 | Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies | 000 | 1 | NIH | 7/22/2022 | $433,679 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA168504 | Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer | 003 | 9 | NIH | 9/21/2022 | $49,889 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA168504 | Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer | 002 | 9 | NIH | 7/18/2022 | $2,160,756 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA100707 | SPORE in Multiple Myeloma | 000 | 19 | NIH | 6/23/2022 | $2,208,656 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA100707 | SPORE in Multiple Myeloma | 001 | 19 | NIH | 9/21/2022 | $48,543 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P30CA006516 | The Dana-Farber/Harvard Cancer Center Bioethics Research Initiative | 010 | 57 | NIH | 4/9/2022 | $115,000 |
|
